As one of the most common oncogenes, mutations in TP53 are associated with hepatocellular carcinoma differentiation, vascular invasion, serum alpha-fetoprotein (AFP) levels, and tumor stage (29, 30). This evidence concerns the gene AFP and neoplasm.